Skip to NavigationSkip to content

FDA rejects Sunovion's ADHD drug dasotraline

Published on 03/09/18 at 11:51am

The US Food and Drug Administration (FDA) have rejected American pharma firm Sunovion’s application to market dasotraline for the treatment of Attention Deficit Hyperactive Disorder (ADHD).

The FDA said that the dual acting dopamine and norepinephrine reuptake inhibitor (DNHI) could not be approved in its current form. The US agency indicated that additional clinical data regarding the tolerability and efficacy of the ADHD drug were needed.

Sunovion however still intend to gain approval for the ADHD medication. The privately owned company intend to meet with the agency in preparation for a resubmission.

“While we are disappointed with the FDA’s decision, we remain confident in the future of dasotraline,” said Antony Loebel, the firm’s chief medical officer and head of Global Clinical Development for Sumitomo Dainippon Pharma Group.

The company is also in the process of developing dasotraline for the treatment of moderate to severe binge eating disorders in adults. A US marketing application is set to be filed at the beginning of 2019.

Louis Goss

Mission Statement is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches